Elevated plasma levels of calcitonin gene‐related peptide in individuals with rosacea: A cross‐sectional case–control study
Journal of the European Academy of Dermatology and Venereology · 2025
DOI: 10.1111/jdv.19954 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von Nita K F Wienholtz und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Rosacea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Augustinus Fonden, Novo Nordisk Fonden.
Abstract (Originalsprache)
Background
Understanding the role of calcitonin gene‐related peptide (CGRP) in the pathogenesis of rosacea might provide new therapeutic avenues for individuals with this disease.
Objective
To compare plasma levels of CGRP between individuals with rosacea and healthy controls.
Methods
In this cross‐sectional case–control study conducted in Copenhagen, Denmark, we collected blood samples from the antecubital vein from adults with rosacea and from healthy controls.
Results
We enrolled 123 individuals with rosacea and 68 healthy controls. After adjusting for age and sex, plasma levels of CGRP were significantly higher in individuals with rosacea (mean, 95% confidence interval: 140.21 pmol/L, 128.50–151.92 pmol/L), compared with controls (110.77 pmol/L, 99.91–120.14 pmol/L, p = 0.002). Plasma levels of CGRP were not affected by age, sex, BMI, concomitant migraine, rosacea sub‐ or phenotype, concomitant disease or current treatment.
Limitations
Participants were not age‐, sex‐ and BMI‐matched. Conclusions and Relevance Elevated plasma levels of CGRP in individuals with rosacea suggest a role of CGRP in the pathogenesis of rosacea. Targeting CGRP signalling might hold therapeutic promise in people affected by this disease. Clinicaltrials.gov listing NCT03872050
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Danish Headache Center, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Department of Dermatology, Bispebjerg and Frederiksberg, Copenhagen University, Copenhagen, Denmark.
- Department of Brain and Spinal Cord Injury, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark.
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
- Department of Anesthesia, Critical Care and Pain Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Nita K F Wienholtz, Alexander Egeberg, Jacob P Thyssen
Förderung
- Augustinus Fonden
- Novo Nordisk Fonden
Zitieren
APA
Wienholtz, N. K. F., Christensen, C. E., Ashina, H., Jørgensen, N. R., Egeberg, A., Thyssen, J. P., & Ashina, M. (2025). Elevated plasma levels of calcitonin gene‐related peptide in individuals with rosacea: A cross‐sectional case–control study. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19954
Vancouver
Wienholtz NKF, Christensen CE, Ashina H, Jørgensen NR, Egeberg A, Thyssen JP, et al. Elevated plasma levels of calcitonin gene‐related peptide in individuals with rosacea: A cross‐sectional case–control study. Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.19954
BibTeX
@article{Wienholtz2025,
author = {Wienholtz, Nita K F and Christensen, Casper E and Ashina, Håkan and Jørgensen, Niklas R and Egeberg, Alexander and Thyssen, Jacob P and Ashina, Messoud},
title = {Elevated plasma levels of calcitonin gene‐related peptide in individuals with rosacea: A cross‐sectional case–control study},
journal = {Journal of the European Academy of Dermatology and Venereology},
year = {2025},
doi = {10.1111/jdv.19954}
}
EUVIMED